Video

Komen NYC Educates Women About Breast Cancer Screening

Author(s):

Linda Tantawi, CEO of Susan G. Komen Greater New York City, discussed the organization’s events that serve as the “pink ribbon connecting the community” and some of their upcoming initiatives to help educate women about breast cancer screening and treatment.

Linda Tantawi, CEO of Susan G. Komen Greater New York City, discussed the organization’s events that serve as the “pink ribbon connecting the community” and some of their upcoming initiatives to help educate women about breast cancer screening and treatment.

Komen’s Third Annual Patient Navigation Initiative will be held June 25, which will have both lay and nurse navigators to discuss what is and isn’t working in patient navigation in the breast cancer space. The discussion will also include who is funding patient navigation, as it is currently not reimbursable through insurance.

In addition, the Sisters for the Cure event will be held on June 29. “It is our effort to really address the disparities in the African American community,” said Tantawi. “We know that African American women are 40% more likely to die from breast cancer than white women, and that is unacceptable.” This initiative will look into what can be done to ensure that African American women have the same quality and access to care as their white counterparts.

Lastly, the NY Metastatic Breast Cancer Conference will be held Oct. 5 through 6. At this event, “we bring the best researchers from all across the country right to New York (for) patients who wouldn’t have access to those researchers,” said Tantawi. “They don’t go to San Antonio, they can’t come here to ASCO, so let’s bring that information right to them.”

To learn more, visit komennyc.org.

Related Videos
Image of man with black hair.
Image of Dr. Fakih.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Image of Doctor with blonde hair.
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.